Crown Bioscience Brings Top Scientists Together to Discuss Best Approaches to Advance Translational Oncology
September 30, 2015 - “Some of the foremost researchers in this field shared information about immuno-oncology therapies and their impact on translational oncology,” said Christopher Murriel, Ph.D., who chaired the event in San Diego. A senior scientist in department of cancer biology at OncoMed Pharmaceuticals, he spoke at the symposium about the use of patient-derived and murine tumor models to predict impacts on cancer stem cells and anti-tumor immunity.
“Translational research, particularly in oncology, holds tremendous potential toward therapeutic drug development and clinical advancement — and the scientists at this symposium presented exciting research that demonstrates how much opportunity exists,” said Murriel. Using clinically-relevant models, Crown Bioscience helps researchers make the best decisions to speed the optimum drug candidates to clinical development.
“We’re pleased to share our expertise and sponsor this forum for scientists and clinicians to discuss the merits of current and future approaches,” said Jean-Pierre Wery, Ph.D., resident of Crown Bioscience. “Our goal is to spur change by helping the industry translate preclinical research into medicines to improve the health and quality of life of patients.”
Henry Li, Ph.D., vice president of translational oncology at Crown Bioscience, discussed the molecular pathway of patient-derived xenograft diseases. Tommy Broudy, Ph.D., general manager and chief scientific officer at Crown Bioscience San Diego, spoke about the adoption of clinically relevant models in oncology therapeutics.
Chief scientists from Decoy Biosystems, Tragara Pharmaceuticals, ImmunGene, Regulus Therapeutics, Ignyta and Pfizer also spoke.
Crown Bioscience will host another symposium Nov. 4 in Boston; details will soon be provided. For more information about how Crown Bioscience works to help researchers improve patient outcomes, visit www.crownbio.com.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
For more information, please visit www.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...